Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Translational Cancer Mechanisms and Therapy

High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors

Lin Lin, Nathanael Kane, Naoko Kobayashi, Evelyn A. Kono, Joyce M. Yamashiro, Nicholas G. Nickols and Robert E. Reiter
Lin Lin
1Department of Urology, University of California, Los Angeles, Los Angeles, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathanael Kane
2Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naoko Kobayashi
1Department of Urology, University of California, Los Angeles, Los Angeles, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evelyn A. Kono
1Department of Urology, University of California, Los Angeles, Los Angeles, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joyce M. Yamashiro
1Department of Urology, University of California, Los Angeles, Los Angeles, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas G. Nickols
1Department of Urology, University of California, Los Angeles, Los Angeles, California.
2Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
3Radiation Oncology Service, VA Greater Los Angeles, Los Angeles, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert E. Reiter
1Department of Urology, University of California, Los Angeles, Los Angeles, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rreiter@mednet.ucla.edu
DOI: 10.1158/1078-0432.CCR-20-2293
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: November 2020 to January 2021

AbstractFull-text HTMLPDF
Total14400234

Cited By

Article Information

DOI 
https://doi.org/10.1158/1078-0432.CCR-20-2293
PubMed 
33219015

Published By 
American Association for Cancer Research
Print ISSN 
1078-0432
Online ISSN 
1557-3265
History 
  • Received June 22, 2020
  • Revision received August 13, 2020
  • Accepted November 17, 2020
  • Published first November 20, 2020.

Article Versions

  • Previous version (November 20, 2020 - 06:16).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2020 American Association for Cancer Research.

Author Information

  1. Lin Lin1,
  2. Nathanael Kane2,
  3. Naoko Kobayashi1,
  4. Evelyn A. Kono1,
  5. Joyce M. Yamashiro1,
  6. Nicholas G. Nickols1,2,3, and
  7. Robert E. Reiter1,*
  1. 1Department of Urology, University of California, Los Angeles, Los Angeles, California.
  2. 2Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, California.
  3. 3Radiation Oncology Service, VA Greater Los Angeles, Los Angeles, California.
  1. ↵*Corresponding Author:
    Robert E. Reiter, University of California Los Angeles, 66-128A Center for the Health Sciences, 10833 LeConte Ave, Los Angeles, CA 90095-1738. Phone: 310-794-7224; Fax: 131-0206-5343; E-mail: rreiter{at}mednet.ucla.edu
PreviousNext
Back to top

This OnlineFirst version was published on January 18, 2021
doi: 10.1158/1078-0432.CCR-20-2293

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors
Lin Lin, Nathanael Kane, Naoko Kobayashi, Evelyn A. Kono, Joyce M. Yamashiro, Nicholas G. Nickols and Robert E. Reiter
Clin Cancer Res January 18 2021 DOI: 10.1158/1078-0432.CCR-20-2293

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors
Lin Lin, Nathanael Kane, Naoko Kobayashi, Evelyn A. Kono, Joyce M. Yamashiro, Nicholas G. Nickols and Robert E. Reiter
Clin Cancer Res January 18 2021 DOI: 10.1158/1078-0432.CCR-20-2293
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Genomic and Epigenomic Profiling of FH-deficient RCC
  • Tarloxotinib Is a Hypoxia-Activated pan-HER Kinase Inhibitor
  • Characterization and Clinical Outcomes of MMR-D SBA
Show more Translational Cancer Mechanisms and Therapy
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement